Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
A double-blind, randomized, saline-controlled study of the efficacy and safety of Euflexxa® for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial)
Seminars in Arthritis and Rheumatism, 06/29/09
Altman RD et al. – Study demonstrates that Euflexxa (1% sodium hyaluronate; IA-BioHA) therapy resulted in significant osteoarthritis (OA) knee pain relief at 26 weeks compared with intra-articular saline (IA-SA). Subjects treated with IA-BioHA also experienced significant improvements in joint function, treatment satisfaction, and HRQoL.
Methods- FLEXX trial: assessing the safety and efficacy of IA-BioHA therapy for knee OA at 26 wks
- Subjects with chronic knee OA were randomized to 3 weekly IA injections IA-SA or IA-BioHA (20 mg/2 ml)
- Primary efficacy outcome: subject recorded difference in least-squares means between IA-BioHA and IA-SA following a 50-foot walk test, measured via 100-mm VAS
- Secondary outcome measures:
- Osteoarthritis Research Society International responder index
- Western Ontario McMaster University Osteoarthritis Index VA 3.1 subscales
- Patient global assessment
- Rescue medication, and
- Health-related quality of life (HRQoL) by the SF-36
- Safety assessed by monitoring and reporting vital signs, physical examination of the target knee following injection, adverse events, and concomitant medications
- 588 subjects randomized to either IA-BioHA (n=293) or IA-SA (n=295), with an 88% 26 wk completion rate
- No differences were noted between the treatment groups at baseline
- In the IA-BioHA group, mean VAS scores decreased by 25.7 mm, vs 18.5 mm in the IA-SA group
- This corresponded to a median reduction of 53% from baseline for IA-BioHA and a 38% reduction for IA-SA
- The difference in least-squares means was -6.6 mm
- Secondary outcome measures were consistent
- Both IA-SA and IA-BioHA injections were well tolerated, with a low incidence of AEs
- Injection-site reactions were reported by 1 (<1%) subject in the IA-SA group and 2 (1%) in the IA-BioHA group
Related Articles
Pain and rheumatology: An overview of the problem
European Journal of Pain, 11/18/09
Relevance Score: 62%
There Is Inadequate Evidence to Determine the Effectiveness of Nonpharmacological and Nonsurgical Interventions for Hand Osteoarthritis: An Overview of High-Quality Systematic Reviews
Physical Therapy, 11/10/09
Relevance Score: 45%
Discriminant Validity of the Western Ontario and McMaster Universities Osteoarthritis Index Physical Functioning Subscale in Community Samples With Hip Osteoarthritis
Archives of Physical Medicine and Rehabilitation, 10/22/09
Relevance Score: 45%
Clinical efficacy evaluation on electroacupuncture for osteoarthritis and observation on biomechanical indexes
Journal of Acupuncture and Tuina Science, 10/19/09
Relevance Score: 45%
Effect of nonsteroidal anti-inflammatory drug plasters for knee osteoarthritis in Japanese: a randomized controlled trial
Modern Rheumatology, 10/12/09
Relevance Score: 45%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Sulfhydryl angiotensin converting enzyme inhibitor promotes endothelial cell survival through nitric oxide synthase, fibroblast growth factor-2 and telomerase cross-talk
Journal of Pharmacology and Experimental Therapeutics, 12/09/09
Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes
Pharmacoepidemiology and Drug Safety, 12/09/09
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder
Expert Opinion in Pharmacotherapy, 12/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


